Published in J Neurooncol on November 03, 2006
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Moving toward molecular classification of diffuse gliomas in adults. Neurology (2012) 1.08
Recent advancements in multimodality treatment of gliomas. Future Oncol (2011) 1.02
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol (2012) 0.98
Management of low-grade glioma. Curr Neurol Neurosci Rep (2010) 0.96
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res (2014) 0.87
Much debated controversies of diffuse low-grade gliomas. Neuro Oncol (2015) 0.80
Medical therapy of gliomas. J Neurooncol (2014) 0.79
Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma. ASN Neuro (2015) 0.79
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. CNS Oncol (2014) 0.77
Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas? Semin Radiat Oncol (2015) 0.77
Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence. J Neurooncol (2017) 0.75
A mathematical model describes the malignant transformation of low grade gliomas: Prognostic implications. PLoS One (2017) 0.75
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood (2010) 3.99
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol (2008) 3.50
Treatment of craniocervical instability using a posterior-only approach: report of 3 cases. J Neurosurg Spine (2014) 3.25
Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation (2003) 3.15
Malignant spinal-cord compression. Lancet Oncol (2005) 2.71
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs (2005) 2.30
Neuromuscular complications of cancer diagnosis and treatment. J Support Oncol (2005) 2.06
Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer (2010) 2.06
The posterior cervical foraminotomy in the treatment of cervical disc/osteophyte disease: a single-surgeon experience with a minimum of 5 years' clinical and radiographic follow-up. J Neurosurg Spine (2009) 2.05
The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer (2002) 1.98
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle (2010) 1.90
Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87
The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg (2012) 1.67
Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia. Muscle Nerve (2008) 1.66
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol (2013) 1.54
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol (2006) 1.53
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res (2008) 1.52
Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res (2009) 1.52
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50
Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol (2009) 1.48
Neurenteric cysts of the spine. J Craniovertebr Junction Spine (2010) 1.48
Gamma Knife surgery for parasellar meningiomas: long-term results including complications, predictive factors, and progression-free survival. J Neurosurg (2011) 1.43
Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol (2010) 1.43
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Gamma Knife surgery for basal ganglia and thalamic arteriovenous malformations. J Neurosurg (2012) 1.39
Neurologic complications of chemotherapy agents. Curr Opin Neurol (2007) 1.39
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab (2010) 1.34
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2004) 1.33
Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol (2013) 1.29
Gamma Knife radiosurgery to the surgical cavity following resection of brain metastases. J Neurosurg (2009) 1.26
Low-grade gliomas: an update on pathology and therapy. Lancet Neurol (2005) 1.26
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol (2011) 1.23
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs (2004) 1.23
Metastasis to nervous system: spinal epidural and intramedullary metastases. J Neurooncol (2005) 1.19
Safety and efficacy of a novel polyethylene glycol hydrogel sealant for watertight dural repair. J Neurosurg (2007) 1.18
Radiation necrosis following treatment of high grade glioma--a review of the literature and current understanding. Acta Neurochir (Wien) (2011) 1.18
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol (2008) 1.18
The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res (2008) 1.17
Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res (2011) 1.13
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res (2007) 1.13
Value of neuropsychological information for improved understanding of the patient with normal-pressure hydrocephalus. J Neurosurg (2005) 1.11
Surgery Insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol (2007) 1.11
Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest (2007) 1.10
Medical management of brain tumor patients. Neurol Clin (2007) 1.09
Medical management of patients with brain tumors. J Neurooncol (2006) 1.09
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs (2010) 1.09
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2010) 1.08
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol (2003) 1.08
Brain metastases. Curr Probl Surg (2004) 1.07
Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys (2011) 1.07
microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. Cancer Res (2014) 1.07
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist (2010) 1.05
Part I: spinal-cord neoplasms-intradural neoplasms. Lancet Oncol (2007) 1.04
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol (2013) 1.03
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys (2010) 1.03
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol (2013) 1.03
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol (2006) 1.02
Advances in brain tumor surgery. Neurol Clin (2007) 1.00
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther (2009) 0.99
Cerebral pressure autoregulation in traumatic brain injury. Neurosurg Focus (2008) 0.99
Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua. J Neurooncol (2005) 0.98
Protein kinase C-alpha-mediated regulation of low-density lipoprotein receptor related protein and urokinase increases astrocytoma invasion. Cancer Res (2007) 0.98
Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep (2008) 0.98
Management of low-grade glioma. Curr Neurol Neurosci Rep (2010) 0.96
Pituitary carcinoma: diagnosis and treatment. Endocrine (2005) 0.95
O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol (2004) 0.94
Initial experience with the eXtend System: a relocatable frame system for multiple-session gamma knife radiosurgery. World Neurosurg (2011) 0.94
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2005) 0.94
An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem (2010) 0.94
Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology (2013) 0.93
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg (2011) 0.93
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol (2012) 0.93
Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol (2012) 0.92
Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma. J Neurooncol (2009) 0.92
Intracranial metastasis of a primary scalp angiosarcoma. Case illustration. J Neurosurg (2002) 0.92
Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol (2010) 0.91
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2008) 0.90
Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. Neuro Oncol (2002) 0.89
CNS Hodgkin lymphoma. Blood (2008) 0.89
Cosmetic and functional outcomes following paramedian and anterolateral retroperitoneal access in anterior lumbar spine surgery. J Neurosurg Spine (2008) 0.89
Unusual presentation of an adult intramedullary spinal teratoma with diplomyelia. Surg Neurol (2006) 0.88